CXCL5 Gene Polymorphism Association with Diabetes Mellitus
- PDF / 94,134 Bytes
- 4 Pages / 592.44 x 751.18 pts Page_size
- 42 Downloads / 241 Views
SHORT COMMUNICATION
© 2008 Adis Data Information BV. All rights reserved.
CXCL5 Gene Polymorphism Association with Diabetes Mellitus Shirin Hasani Ranjbar,1 Parvin Amiri,1 Issam Zineh,2 Taimour Y. Langaee,2 Mahsa Namakchian,1 Ramin Heshmet,1 Mohammadali Sajadi,3 Mohammadreza Mirzaee,3 Ebrahim Rezazadeh,3 Parisa Balaei,3 Javad Tavakkoly Bazzaz,1 Miguel A. Gonzalez-Gay,4 Bagher Larijani1 and Mahsa M. Amoli1 1 2 3 4
Endocrinology and Metabolism Research Centre, Tehran University of Medical Sciences, Tehran, Iran University of Florida, Centre for Pharmacogenomics, Gainesville, Florida, USA Rafsanjan University of Medical Sciences, Rafsanjan, Iran Division of Rheumatology, Hospital Xeral-Calde, Lugo, Spain
Abstract
Background: CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is a chemokine that has a role in the development of cardiovascular and other diseases. We have previously scanned the full length CXCL5 gene and reported the –156G>C (rs352046) polymorphism in the promoter region of this gene. Objective: The aim of this study was to examine whether there was an association between this polymorphism and type 2 diabetes mellitus or its microvascular complications in an Iranian population. Methods: A total of 230 patients with type 2 diabetes were recruited from Rafsanjan, in the south-east of Iran; 102 healthy control subjects were recruited from the same area. The region containing the CXCL5 –156G>C polymorphism was genotyped by PCR amplification and restriction fragment length polymorphism analysis, and allele frequency data were analyzed using STATA 8 software. Results: We observed that patients with type 2 diabetes had a higher frequency of carrying either the G/C or C/C genotype compared with healthy controls (C/G + C/C vs G/G; p = 0.004; odds ratio [OR] 2.17; 95% CI 1.27, 3.80). In addition, the frequency of allele C was significantly increased in patients with diabetes compared with controls (p = 0.01; OR 1.72; 95% CI 1.07, 2.86). No association was found between this polymorphism and diabetic microvascular complications. Conclusions: Our findings suggest a role of CXCL5 in the pathogenesis of diabetes. The mechanism behind this role needs to be investigated further. Moreover, replications in other populations with larger sample sizes are required to confirm these findings.
Background and Objective CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), belongs to the CXC subfamily of chemokines and is expressed by epithelial cells after stimulation with pro-inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor-α (TNFα), inducing polymorphonuclear neutrophil (PMN) adhesiveness.[1] Zimmerman and colleagues[2] have shown that CXCL5 is also released by stimulated endothelial cells in human lung and other tissues, and can act in concert with
IL-8 to induce neutrophil pro-adhesive activity. Higher levels of CXCL5 have been detected in patients with chronic pancreatitis compared with healthy individuals; and levels are als
Data Loading...
